INTRODUCTION
Medullary cystic kidney disease (MCKD; MIM 603860) and familial juvenile hyperuricemic nephropathy (FJHN; MIM 162000) are autosomal-dominant disorders characterized by alteration of urinary concentrating ability leading to polyuria and polydipsia, tubulo-interstitial fibrosis, hyperuricaemia and gout, and renal cysts at the cortico-medullary junction (1) . Although MCKD and FJHN are heterogeneous in terms of age at onset, clinical features and presence of cysts, they invariably lead to chronic kidney disease (CKD) during the second or third decade of life.
Two loci for MCKD have been mapped on chromosomes 1q21 (MCKD1) (2) and 16p12 (MCKD2) (3) . FJHN was mapped to the same locus as MCKD2 (4) , leading to the hypothesis that they could be allelic diseases (5) . MCKD2 and FJHN were indeed shown to be caused by mutations in the same gene UMOD that encodes uromodulin and are collectively referred to as uromodulin-associated kidney diseases (UAKD) (6) .
Uromodulin (or Tamm -Horsfall protein) is the most abundant protein in human urine under physiological conditions (7) . It is a GPI-anchored protein that is exclusively expressed by epithelial cells lining the thick ascending limb of Henle's loop (TAL) and of the early part of the distal convoluted tubule (DCT). A proteolytic cleavage sheds uromodulin into the tubule lumen (8) where it is found as a high molecular weight polymer. Despite being discovered more than 50 years ago (9) , uromodulin function remains somewhat elusive (10) . Studies on Umod knock-out mice demonstrated that it plays a protective role against urinary tract infections (11, 12) and calcium oxalate crystal-induced urothelial damage (13, 14) . It is worth to note that mice lacking uromodulin did not show any clinical or histological feature of UAKD for up to 3 years of age (15) , suggesting a gain-of-function effect of UMOD mutations. Uromodulin was also shown to have an immunoregulatory role (16) (17) (18) (19) (20) . Interestingly, common polymorphisms in the UMOD gene have been recently linked to an increased risk of CKD (21) . These variants are associated to elevated uromodulin urinary concentrations (22) , raising new questions about the biological importance of this protein in kidney function.
To date, more than 50 UMOD mutations have been reported in UAKD patients. All but three (in-frame deletions) are missense changes that are clustered in the N-terminal half of the protein. Several in vitro studies demonstrated that mutations in uromodulin lead to trafficking defect and intracellular retention of mutant protein (23 -28) . This is consistent with findings in patients, i.e. the presence of uromodulin aggregates within the cytoplasm of tubular cells and the dramatic reduction of urinary uromodulin excretion (23, 29) .
Despite the extensive in vitro studies, the molecular bases of UAKD are not elucidated. In particular, the questions of what leads to mutant uromodulin retention, whether it exerts a dominant negative and proteotoxic effect, and how this accumulation relates to progressive tubulo-interstitial damage and renal dysfunction, are still open. To gain insight into the pathogenesis of UAKD, we generated and characterized the first in vivo model for these diseases, i.e. a transgenic mouse expressing mutant uromodulin (Tg UmodC147W ). The mutation introduced in the murine protein (C147W) corresponds to the human mutation C148W that we previously identified in UAKD patients and extensively characterized in vitro (23) . When compared with expression-matched transgenic mice for wild-type protein (Tg Umodwt ), Tg UmodC147W mice specifically show progressive signs of renal damage, i.e. tubulo-interstitial fibrosis with inflammatory cell infiltration and tubule dilation, urinary concentrating defect and renal failure. These features are associated to endoplasmic reticulum (ER) retention of uromodulin and ultrastructural alteration of the ER membranes. Tg UmodC147W mice hence represent a unique model of UAKD recapitulating most of the disease features and providing critical insights into a possible pathogenic mechanism.
RESULTS

Generation of uromodulin transgenic mice
The uromodulin transgene comprises a Umod minigene, including a 3 kb promoter fragment, the first non-coding exon and intron 1, the remaining coding sequence from exon 2 to exon 11 and the entire 3 ′ UTR (Fig. 1A) . The promoter fragment used was shown to be sufficient to drive TAL/ DCT-specific expression in mouse (30, 31) .
To specifically discriminate transgenic uromodulin from the endogenous one, we inserted an HA-tag between the leader peptide and the first EGF-like domain (i.e. between S26 and T27). We previously assessed that the insertion of an HA-tag in uromodulin at this position does not alter protein trafficking nor protein polymerization when expressed in renal tubular (MDCK) cells (32) . Mutant uromodulin was obtained through insertion of mutation C147W, homologous to UMOD mutation C148W that we identified in UAKD patients (23) . Linearized wild-type and C147W transgenes were injected into FVB mouse strain to obtain eight and five founder animals, respectively.
The wild-type line #416 (referred throughout the text as Tg
Umodwt
) and the mutant line #958 (referred throughout the text as Tg UmodC147W ) resulted to be best matched for transgene expression level and were hence chosen for further characterization. Southern blot analysis revealed insertion of the full transgene in three and two copies in Tg
Umodwt and Tg UmodC147W lines, respectively (Supplementary Material, Fig. S1 ). Moreover, transmission of the transgene in both Tg
Umodwt and Tg UmodC147W lines was stable with proper Mendelian segregation and there is no apparent copy number loss (data not shown). Transgenic animals from both lines were viable, apparently healthy and undistinguishable from control non-transgenic littermates.
The kidney-specific expression of transgenic uromodulin was confirmed by western blot analysis in the Tg Umodwt and Tg UmodC147W lines (Fig. 1B) . The transgenic protein showed the expected size of 120 kDa and a lower molecular weight isoform corresponding to the ER precursor (see Fig. 2A ) and as for endogenous protein was found in urine (see Fig. 2B ).
Within the kidney, both wild-type and mutant transgenes are correctly expressed in the TAL/DCT segments, as assessed by immunofluorescence co-staining with different nephron segment markers (Fig. 1C) .
The transgenic uromodulin transcript was present at comparable levels in both lines, wild-type mRNA being on average 0.7-fold the mutant one. In both lines, the transgene is expressed at a lower level than endogenous Umod ( 80% for the mutant mRNA and 50% for the wild-type one; data not shown).
Uromodulin trafficking defect in Tg
UmodC147W animals
To assess the trafficking and secretion of wild-type and mutant uromodulin, we carried out western blot analysis on both kidney extracts and urine samples. We first noticed that the amount of transgenic uromodulin in Tg UmodC147W kidneys was remarkably higher when compared with Tg Umodwt mice ( Fig. 2A, left) . Moreover, the transgenic protein in Tg UmodC147W kidneys showed enrichment of a lower molecular weight band of 100 kDa, representing immature uromodulin with ER-type glycosylation ( Fig. 2A, right) . In contrast, urinary levels of both transgenic and total uromodulin were dramatically reduced in Tg UmodC147W mice, very similar to the situation in UAKD patients (29) (Fig. 2B) .
Immunohistochemistry for transgenic uromodulin showed a very different distribution in the two lines (Fig. 3) . Tubular staining of 12 and 24 weeks-old Tg Umodwt mice revealed homogeneous cytoplasmic distribution with enhanced signal at the apical side. In 12 weeks-old Tg UmodC147W animals, the signal for transgenic uromodulin lacked the apical reinforce and showed a specific intracellular enrichment in a spottedlike pattern. The same distribution of transgenic uromodulin was observed at 24 weeks, associated to a clear accumulation of the protein in coarse, dense aggregates in several cells.
Interestingly, in some Tg UmodC147W kidney sections, we observed the presence of extra-tubular uromodulin, either within interstitial cells or in the renal interstitium (Supplementary Material, Fig. S2 ). Also, mutant uromodulin seemed to be enriched on the basolateral side of some epithelial cells. These findings are suggestive of interstitial release of uromodulin.
Taken together, these results show that mutant uromodulin trafficking to the plasma membrane is impaired, with ER retention, accumulation in the kidney and decrease in urinary excretion similar to the characteristics of the human disease.
Mutant uromodulin is retained in the ER
To further demonstrate ER retention of mutant uromodulin, we investigated the distribution of transgenic protein by immunofluorescence analysis on kidney sections ( Fig. 4A and B). Consistent with immunohistochemistry data, transgenic wild-type uromodulin was enriched at the apical membrane of epithelial cells lining the TAL. This staining pattern is similar to what is observed for native uromodulin (data not shown). On the contrary, mutant uromodulin was highly enriched in the cytoplasm of the majority of TAL tubules in Umodwt and Tg UmodC147W mice. Kidney sections were stained with antibodies against HA (red) and nephron segment-specific markers (green). Representative merged images for each co-staining are shown. Transgene expression specifically co-localizes with ROMK and uromodulin. No transgene expression was detected in tubule sections positive either for aquaporin-1 (proximal tubules) or aquaporin-4 (collecting ducts). Kidney samples from control animals (non-transgenic animals) are negative for the HA signal (inset). Bar ¼ 100 mm.
Tg
UmodC147W kidneys, where it co-localized with the ER chaperones calnexin (Fig. 4B ) and GRP78/BiP (Supplementary Material, Fig. S3 ). Accumulation in post-ER/pre-Golgi vesicles was excluded by co-staining with p115 and GM130 (Supplementary Material, Fig. S3 ). Moreover, mutant uromodulin was forming intraluminal protein casts, potentially resulting from accumulation of epithelial cellular debris and exfoliation (see below) or from mutant protein escaping ER quality control and being secreted in the tubule lumen, where it could aggregate with endogenous wild-type uromodulin. Intracellular and intraluminal aggregation of mutant uromodulin were invariably observed in the majority of TAL profiles in 12 and 24 weeks-old kidneys examined. It must be noted that the ER aggregation of mutant uromodulin observed in Tg UmodC147W kidneys is strikingly similar to what seen in a renal biopsy from an UAKD patient harbouring mutant uromodulin G210R. Through in vitro studies we verified that this mutation causes uromodulin retention in the ER (data not shown). In the patient's kidney sample, uromodulin is mostly localized in intracellular aggregates that are positive for calnexin staining (Fig. 4C) . It is worth to note that both in Tg UmodC147W mice and in UAKD patient, the pattern of calnexin distribution is dramatically altered, possibly reflecting abnormal structure of the ER membranes (see below).
Impaired urinary concentrating ability and mild renal failure in Tg
UmodC147W mice
At baseline, the Tg UmodC147W mice exhibited a significant polyuria, with diluted urine, higher plasma osmolality, a trend for higher vasopressin levels and a significant polydipsia, when compared with the Tg Umodwt (Table 1) . They also showed a mild renal failure, with increased plasma urea and creatinine levels, as well as increased urinary calcium excretion and lower urine pH (Table 1 ). In contrast, the clinical and biological parameters of the Tg Umodwt mice were similar to age-and gender-matched controls.
We further assessed the polyuria in the Tg UmodC147W mice by performing a water deprivation test (Table 2) . When compared with Tg Umodwt , the Tg UmodC147W mice were unable to significantly increase their urine osmolality, resulting in a higher urine volume. These modifications occurred despite a similar increase in plasma vasopressin, indicating that the urinary concentrating defect was of renal origin. Further quantification of target mRNA revealed that water deprivation induced a similar or even higher increase in the expression of vasopressin (AVP) and vasopressin target genes including aquaporin-2 (AQP2), vasopressin receptor-2 (AVPR2) and the urea transporters UT-A1-3 in the Tg UmodC147W versus Tg Umodwt kidneys (Supplementary Material, Fig. S4 ).
Progressive tubulo-interstitial damage in Tg UmodC147W mice
Kidneys from 12 and 24 weeks-old Tg Umodwt mice had completely normal histological features at light microscopy (Supplementary Material, Fig. S5 ).
Tg UmodC147W at 12 weeks of age displayed mild-tomoderate tubular dilation, accompanied by sparse tubular atrophy and focal areas of interstitial inflammatory infiltration and fibrosis. Some dilated tubules were filled with proteins casts ( Fig. 5A and B) .
Progression of tubulo-interstitial damage was clearly seen in kidneys from 24 weeks-old animals, showing increased fibro- sis ( Fig. 5C ), tubular cysts in the cortico-medullary area ( Fig. 5D and E) and damaged tubules with cells containing vesicular structures and dense material (Fig. 5F ). Noteworthy, the cystic tubules that could be observed were positive for the anti-HA signal (Supplementary Material, Fig. S6A and B) and negative for aquaporin-1 and -4 (data not shown), suggesting that cystic dilation mainly affects tubules expressing transgenic mutant uromodulin. Moreover, tubular atrophy and an increased number of inflammatory foci were observed. Numerous tubules displayed altered cells, detaching from the basement membrane or partially shedding HA-positive cytoplasmic content (Supplementary Material, Fig. S6C ). Additionally, tracts of increased thickness or multilayered tubular basement membrane, or gaps of the tubular basement membrane itself were observed. By electron microscopy, tubular cells displayed enlarged cytoplasm containing expanded ER seen as many parallel or sub-parallel folded membranes, apparently lacking ribosomes. Other tubules showed cytoplasmic accumulation of electron-dense protein droplets. Numerous cells had alterations highly suggestive of a necrotic process, i.e. dilated cytoplasm with clear rounded areas derived from digestive activity, loss of cellular membrane integrity and destruction of mitochondria and other cytoplasmic organelles (Fig. 6) .
Active caspase-3 staining did not reveal any significant difference between control, Tg Umodwt and Tg UmodC147W mice either at 12 and 24 weeks of age (data not shown), indirectly confirming the electron microscopic data in favour of a necrotic process progressively damaging tubule cells.
Selective tubular damage in the Tg
The presence of tubular cysts and of luminal exfoliated cells that were HA-positive suggested that expression of mutant uromodulin elicited a selective damage originating from the TAL cells. To assess this hypothesis, we analysed the renal expression of genes involved in the TAL and other tubular segments (Fig. 7) . There was a significant decrease in the mRNA-encoding transporters specifically expressed in the TAL (NKCC2, ROMK and ClC-Kb) in the Tg UmodC147W kidneys when compared with Tg Umodwt ones, contrasting with the unchanged expression of proximal tubule (AQP1), collecting duct (ENAC, AQP2, AVPR2) and ubiquitous (Na + -K + -ATPase) markers (Fig. 7A ). Immunoblotting confirmed a strong decrease in the expression of NKCC2 in membrane fractions from Tg
UmodC147W kidneys, when compared with AQP2 and Na + -K + -ATPase (Fig. 7B) . This was further evidenced by immunostaining, with a much weaker apical signal for NKCC2 observed in TAL segments of Tg UmodC147W kidneys. The fewer NKCC2-positive tubular profiles were mostly damaged (Fig. 7C) consistently with what observed in immu- nostaining for transgenic uromodulin. These data demonstrate a selective TAL cells damage in Tg UmodC147W mice.
Progressive inflammatory process in kidneys of Tg UmodC147W mice
The remarkable inflammation process observed in Tg
UmodC147W
kidneys was further characterized by expression analysis of inflammatory cells markers. A significant upregulation of all tested genes was observed in Tg UmodC147W mice when compared with Tg Umodwt , particularly markers of macrophages and granulocytes (Fig. 8A) . Noteworthy, also markers of cell proliferation, i.e. Ki67 and Cyclin E1, were significantly upregulated.
The progressive development of inflammatory cell infiltration in Tg UmodC147W mouse kidneys was also confirmed by immunostaining showing a dramatic increase of the number of interstitial macrophages between 12 and 24 weeks of age, particularly in the renal medulla (Fig. 8B) .
DISCUSSION
Dominant mutations in the UMOD gene encoding for uromodulin cause UAKD (6), which are characterized by impairment of urinary concentrating ability, hyperuricaemia, cysts at the cortico-medullary junction and tubulo-interstitial alterations leading to progressive renal failure (1).
We here report on the generation and characterization of the first in vivo model for UAKD. Transgenic mice expressing mutant uromodulin (Tg UmodC147W ) recapitulate most of the clinical and biochemical features associated with the human disease, including ER accumulation of mutant uromodulin in the cells lining the TAL segment, decreased urinary excretion of uromodulin and progressive tubulo-interstitial injury leading to urinary concentrating defect and chronic renal failure.
The transgenic protein expressed in the Tg UmodC147W mice harbours the C147W mutation, which affects the disulphide bond pattern in the EGF-like domain III and corresponds to the human C148W mutation identified in UAKD and extensively characterized in vitro (23) . All the studies were conducted in comparison to an expression-matched transgenic line expressing wild-type uromodulin (Tg Umodwt ) in order to exclude any effect due to uromodulin overexpression. As expected, on the basis of the promoter used (30), transgenic murine uromodulin was restricted to the TAL/ early DCT segments of mouse kidneys, mimicking the wildtype pattern.
The expression of transgenic mutant uromodulin in Tg UmodC147W kidneys led to clear and progressive tubulointerstitial damage in the renal medulla. We observed a sustained increase in the interstitial fibrosis from 12 to 24 weeks of age, strictly correlated to infiltration of inflammatory cells, tubular cystic dilation and atrophy (Fig. 5G) . These lesions mirror the typical histopathological features resulting from mutant uromodulin in man (33) and, to our knowledge, the Tg UmodC147W mouse is the first animal model for UAKD. Indeed, recently reported mice obtained by chemical (N-ethyl N-nitrosourea, ENU) mutagenesis and expressing uromodulin variant A227T (Umod A227T ) did not show any histopathological sign up to 6 months of age (34) . Differences between the two models could be due to the fact that the missense change introduced in the Umod A227T mouse has not been found in UAKD patients as opposed to the Tg UmodC147W mouse, to the total uromodulin expression level or to the different genetic background (C3H versus FVB) of the strains.
The progression of the tubulo-interstitial damage in Tg UmodC147W mice is characterized by a remarkable and progressive inflammatory process, as observed in UAKD patients (5, 33) . These findings are strongly supported by a significant upregulation of inflammatory cell markers indicative of a mixed cellular infiltrate mainly composed by granulocytes and macrophages.
The inflammatory process in the kidneys of Tg UmodC147W mice could be triggered by necrosis of TAL cells (35) , which was discernible as cell swelling and presence of cellular debris in the lumen. Additionally, uromodulin release in the interstitium (as suggested by data shown in Supplementary Material, Fig. S2 ), secondary to its accumulation in Tg UmodC147W kidneys and tubular damage, could induce an inflammatory response by acting as an adjuvant and possibly as an auto-antigen. Several in vitro studies have indeed demonstrated that uromodulin is a pro-inflammatory molecule, able to interact with and activate components of the immune system, including monocytes (36) , neutrophils (37, 38) and myeloid dendritic cells via Toll-like receptor 4 (16, 39) . Moreover, increase in the uromodulin serum level, possibly as a consequence of interstitial release, was reported in some UAKD patients (27) and very recently shown to be positively correlated with pro-inflammatory cytokines in a cohort of CKD patients (40) . We believe that Tg UmodC147W mice represent a unique tool to elucidate the role of uromodulin in the activation of immune response and in the progression of renal damage.
Tg UmodC147W mice exhibit a significant loss of urine concentrating ability with polyuria, polydipsia and reduced urine osmolality. Additionally, expression of mutant uromodulin in Tg UmodC147W mice leads to mild renal failure. These findings are very similar to the clinical features observed in UAKD patients (23, 29) . The defective urinary concentration ability of Tg UmodC147W mice is present despite normal levels and reactivity of vasopressin and its target genes, expressed in segments other than the TAL, and is likely due to a specific TAL dysfunction. Indeed, our data show that Tg UmodC147W kidneys are characterized by specific defects affecting the TAL segment, including defective expression of NKCC2, ROMK, ClC-Kb, whose activity is necessary for the formation of a hypertonic interstitium that is needed to concentrate urine, a process that is clearly defective in Tg UmodC147W mice. Taken together, our data suggest that impaired TAL function is a consequence of a gain-of-function effect of UMOD mutations. Intracellular uromodulin accumulation damages TAL cells leading to a functional/structural loss of that segment, with loss of critical transporters including NKCC2.
In contrast with the human disease, we did not observe hyperuricaemia in Tg UmodC147W mice. Hyperuricaemia in UAKD is generally considered as a consequence of a compensatory mechanism for salt-wasting leading to increase in the reabsorption of both sodium and urate in the proximal tubule (41, 42) . We believe that the lack of hyperuricaemia in Tg UmodC147W mice despite obvious manifestations of defective transport processes in the TAL is due to the uricase (urate oxidase) activity that catalyses the conversion of uric acid to allantoin and is present in rodents but not in humans (43) . This could also be the reason for the lack of hyperuricaemia in mouse models of salt-losing tubulopathies (44, 45) . Interestingly, the presence of structural changes and kidney damage similar to the human condition in Tg UmodC147W mice suggest that hyperuricaemia per se does not have a causal role in UAKD. It must be noted that the Tg UmodC147W mice exhibited a significant increase in Ca 2+ urinary excretion that could be a consequence of altered NKCC2 activity affecting paracellular Ca 2+ reabsorption (46) . In turn, the hypercalciuria may explain the lower urinary pH of the Tg UmodC147W mice, as it was recently demonstrated that activation of the Ca 2+ -sensing receptor by increased luminal Ca 2+ leads to urinary acidification and polyuria (47) . In the absence of significant modifications in terms of natriuresis and kaliuresis, one may suggest that the defect of TAL function in Tg UmodC147W mice is probably compensated by transport mechanisms operating in more distal segments (including the collecting ducts).
Despite comparable expression level of the transgene in Tg UmodC147W versus Tg Umodwt mice, transgenic uromodulin was highly enriched in Tg UmodC147W kidney extracts. In particular, we demonstrated for the first time in vivo accumulation of mutant uromodulin in the ER of TAL cells. ER retention of mutant uromodulin, likely due to protein misfolding, is in agreement with published in vitro studies (23) (24) (25) (26) (27) (28) . Interestingly, we observed altered distribution of calnexin in TAL cells of Tg UmodC147W kidneys, suggesting that retention of mutant uromodulin induced alteration of ER membrane structure. This also happens in the human disease, as a striking similarity for the calnexin distribution pattern in TAL tubules was observed in an UAKD patient biopsy. Alteration of the ER stack structure was confirmed by ultrastructural analysis showing hyperplasia of ER membranes in distal tubule cells. Such an expansion of ER membranes in the absence of stack dilation might suggest a compensatory mechanism for the ER retention of mutant uromodulin by increasing the ER volume (48) . Intracellular accumulation of mutant uromodulin resulted in a dramatic reduction of its urinary level in Tg UmodC147W mice. All these findings are remarkably similar to what seen in the kidneys and urine of UAKD patients (23, 26, 29, 33, 49) . Uromodulin intracytoplasmic enrichment and reduced urinary excretion were also reported in the Umod A227T mouse (34) . In this context, recent results relative to a transgenic mouse line expressing C148W mutant human uromodulin and showing accumulation of only the murine wild-type uromodulin are puzzling (50, 51) . As no additional data on the mice phenotype were reported, it seems likely that the expression level of mutant human uromodulin in that mouse line was not sufficient to be progressively accumulated in TAL cells. A still open question relates to the potential dominant negative role of mutant uromodulin on the trafficking to the plasma membrane of wild-type protein. The extent of urinary level reduction in Tg UmodC147W mice and UAKD patients and the fact that we were unable to detect any staining for endogenous wild-type uromodulin (i.e. UMOD-positive/ HA-negative) on the apical membrane of TAL cells in Tg UmodC147W mice strongly suggest that this could indeed be the case.
Our findings in the Tg UmodC147W mouse model support the designation of UAKD as uromodulin-storage diseases (23, 29, 41) . From the evidence reported here, we propose a model of UAKD pathogenesis (Fig. 9) , in which the key primary event is ER retention and aggregation of mutant uromodulin in the TAL cells. Progressive accumulation of mutant uromodulin in the ER leads to TAL structural injury, possibly through the activation of cell stress responses as the unfolded protein response (52) or other ER stress mechanisms (53) . These pathways could also play a role along with the cellular damage of the TAL segment in eliciting an inflammatory response resulting in a progressive interstitial fibrosis and tissue scarring, a final common pathway for many CKDs. In this context, renal cysts, shown here for the first time to be of TAL origin in UAKD, could be a consequence of progressive TAL cellular damage and secondary proliferation. All these cellular events coexist in 18-24 weeks-old Tg UmodC147W mouse kidneys, resulting in mutual stimulation leading to functional injury of the TAL segment eventually affecting the urinary concentrating ability, and to mild renal failure. Future studies on Tg UmodC147W mice at different age points will help to address the clinical relevance and contribution of each factor.
In summary, Tg UmodC147W mice represent a clinical and pathological model of human UAKD and are a unique tool to further dissect the pathophysiology of renal damage associated to uromodulin mutations. The Tg Umod mice could also provide a useful model to assess the role of uromodulin in CKD and to investigate pathways associated with tubulo-interstitial and ER-storage diseases (54) . 
MATERIALS AND METHODS
Generation and genotyping of Tg
Plasma and urine analyses
Urine and plasma were obtained on age-and gender-matched transgenic and control mice (females, aged 18-21 weeks). They were housed in light-and temperature-controlled room with ad libitum access to tap water and standard chow (Diet AO3, SAFE, France). Plasma samples and overnight urine collections were obtained at baseline in individual metabolic cages, after appropriate training. Blood was collected by venous puncture, and plasma samples were kept at 2208C.
The urinary concentrating ability was tested after 12 h water deprivation (55) . Blood samples were obtained at the time of sacrifice by decapitation. The sampling procedures were exactly similar in both the groups.
Analytic procedures
Urinary creatinine and electrolytes, plasma urea, creatinine (enzymatic determination), uric acid and bicarbonate were measured on a Synchron CX5 analyzer (Beckman Coulter, Fullerton, CA, USA). Plasma sodium and potassium values were determined using a Kodak Ektachem DT60 II Analyzer (Johnson & Johnson, New Brunswick, NJ, USA). Osmolality was measured on a Fiske Osmometer (Needham Heights, MA, USA). Urinary pH was measured using a glass pH electrode (DGI101-SG) on a Mettler Toledo T50 (Zaventem, Belgium). Plasma AVP levels were measured using EIA (Peninsula Laboratories, San Carlos, CA, USA) (44, 55) .
Retrotranscription and real-time PCR
Total RNA from whole kidney and brain was obtained by homogenization in TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and purification on RNeasy columns (Qiagen, Inc., Galthersburg, MD, USA) or by use of the Aurum TM Total RNA Fatty and Fibrous Tissue Kit (Bio-Rad, Hercules, CA) following the manufacturer's protocol. Genomic DNA was removed by on-column digestion with DNase I treatment (Qiagen). Total RNA was reverse-transcribed with SuperScript III Reverse Transcriptase (Invitrogen).
Probe-based chemistry. Expression of transgenic uromodulin, endogenous uromodulin, claudin 16 and beta-actin genes was analysed in age-matched transgenic animals (12 weeks, n ¼ 3 pairs). Primers for target genes and corresponding probes were designed using the Universal Probe Library system (56) with online tools (https://www.roche-applied-science.com/sis/rtpcr/ upl/adc.jsp). For primer sequences, probe numbers and PCR conditions, see Supplementary Materials and Methods. All reactions were performed in triplicate and repeated at least twice. The expression of wild-type and mutant transgenic uromodulin transcripts was normalized to either claudin 16 or beta-actin. SYBR Green chemistry. Expression of specific tubule-segment markers, inflammatory and proliferation target genes was analysed in age-and sex-matched transgenic animals (18 -20 weeks, n ¼ 5 pairs) by relative RT-qPCR with a CFX96 TM RealTime PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA) using iQ TM SYBR Green Supermix (Bio Rad) detection of single PCR product accumulation. Specific primers were designed using Primer3 (57) and the efficiency of each set of primers was determined by dilution curves (see Supplementary Materials and Methods). RT-qPCR analyses were performed in duplicate. For reaction conditions, see Supplemental Materials and Methods. The stability of the reporter genes (Actb, Gapdh, Ppia, Arbp and Hprt1) expression was verified using the GeNorm 3.4 program (58,59) and they were selected to calculate the normalization factor.
Immunoblotting
Mouse tissues were homogenized either at 48C in lysis buffer [0.32 M sucrose, 5 mM HEPES, pH 7.4, and protease-inhibitor cocktail (1:1000) (Sigma-Aldrich Corporation, St Louis, MO, USA) or as described previously (55) . Membrane fractions were obtained by centrifugation at 1000g for 15 min at 48C. The resulting supernatant was either kept at 2808C (as the 'total extract' fraction) or centrifuged at 100 000g for 120 min at 48C. The resulting pellet (membrane fraction) was resuspended in a buffer containing 20 mM Tris -HCl pH 8, 150 mM NaCl, 60 mM N-octylglucoside (Sigma-Aldrich Corporation) and protease inhibitor cocktail (Sigma-Aldrich Corporation). Membrane fractions were loaded on an 8% SDS -PAGE gel in reducing conditions and analysed by western blot. Where indicated, membrane fractions were treated with endo-b-Nacetylglucosaminidase H (Endo H; New England Biolabs) according to the manufacturer's protocol. Urine samples were loaded on a 7.5% SDS -PAGE gel in non-reducing conditions and analysed by western blot. When needed, quantification of the relative band intensities on the films was determined with a StudioStar Scanner (Agfa-Gevaert, Mortsel, Belgium) using the NIH-Image V1-57 software.
Renal tissue collection and preparation
To collect renal tissue, animals were sacrificed either by decapitation, or anaesthetized by cloralium hydrate and perfused with a 4% paraformaldehyde solution. In both cases, kidneys were taken and fixed in 4% paraformaldehyde solution for additional 16 h. For routine light microscopy stainings and immunoperoxidase, samples were dehydrated and paraffin-embedded. For immunofluorescence staining, kidneys were embedded in optimum cutting temperature embedding medium (Tissue-Tek, Electron Microscopy Sciences, Hatfield, PA, USA), snap-frozen in a mixture of isopentane and dry ice, and stored at 2808C. For transmission electron microscopy, 1 mm 3 renal cortex pieces were fixed in a mixture of paraformaldehyde, glutaraldehyde and phosphate buffer, and embedded in resin. 
Light and electron microscopy analyses
Immunohistochemistry and immunofluorescence
Sections (3 -6 mm thick) were processed with standard immunohistochemistry protocol using the specific primary antibodies listed below. Sections were viewed under a Zeiss Axioscope 40FL microscope, equipped with AxioCam MRc5 digital video camera or under a Leica DMR coupled to a Leica DC300 digital camera (Leica, Heerbrugg, Switzerland).
Images were recorded using AxioVision software 4.3 and analysed by the AxioVision analysis module (Carl Zeiss SpA).
Immunofluorescence was carried out on tissue sections (10 mm thick) using the primary antibodies listed below. All slides were visualized under the Leica TCS SP2 confocal microscope or the Leica DM 5000B fluorescence upright microscope (Leica DFC480 camera, Leica DFC Twain Software).
Antibodies
Antibodies used: sheep antibodies against uromodulin (Meridian Life Science, Saco, ME, USA) and (Abcam); rat monoclonal antibodies against HA (Roche, Indianapolis, USA) and mouse macrophages (F4/80) (Serotec, Oxford, UK); mouse monoclonal antibodies against HA (Covance, Inc., Princeton, NY, USA) and the a1-subunit of Na + -K + -ATPase (Upstate, Temecula, CA, USA); rabbit polyclonal antibodies against NKCC2 (Chemicon, Temecula, CA, USA), aquaporin 2 (Sigma-Aldrich Corporation), aquaporin 1 and aquaporin 4 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), ROMK (United States Biological, Swampscott, MA, USA), calnexin (Sigma-Aldrich Corporation), p115 and GM130 (kind gifts of Prof. Antonella De Matteis) (60); goat polyclonal antibody against GRP78/BiP (Santa Cruz).
Statistical analyses
Data are means + SEM. Comparisons between groups were performed using two-tailed unpaired t-test (Prism software; GraphPad, San Diego, CA, USA). Significance level was P , 0.05.
